The ageing process is naturally accompanied by changes in people's cognitive processes. The European population ageing is a challenge for the European social policy and for the mental health professionals. New technologies can play an important role in the neurocognitive stimulation area as they possess characteristics that might reduce the anxiety levels of patients participating in neurocognitive stimulation or assessment programs. In particular, serious games provide a setting that can be explored to improve the easy access to neurocognitive stimulation and assessment, regardless of place and time, at a lower cost then traditional approaches. This paper presents a serious game aiming to analyse neurocognitive deficits and stimulate the players' deficitary neurocognitive processes. This game is built on top of sound neurocognitive psychotherapy for adults, mainly addressing the cognitive processes of attention and memory. The game will simulate real world scenarios, allowing a better generalization process due to ecological validity.
The paper by , published in Journal of Psychopharmacology, January 9th 2021, provides important information about the use of subcutaneous esketamine in real-world patients. However, some points need to be clarified: First, the majority of patients received the doses of 1 mg/kg, but the paper does not make clear whether those patients were the same who presented a better response. Second, the best response was observed in patients with comorbidity anxiety disorder. The diagnostic and statistical manual of mental disorders -fourth edition (DSM-IV) was used as the diagnostic criteria to include and exclude patients, anxiety disorders in this version of the DSM included post-traumatic stress disorder (PTSD) and obsessive-compulsive disorder (OCD), we do not comprehend why the diagnostic and statistical manual of mental disorders -fifth edition (DSM-5) was not used since it was published in 2013 and data were collected between 2017 and 2018 (American Psychiatric Association, 1994Association, , 2013. Moreover, these patients with anxiety disorders were in use of benzodiazepines (BZD)? How many of them had PTSD or OCD? Third, Table 2 is misleading, mostly because it suppresses two of the duration parameter classes used in the Maudsley Staging Method (MSM), which are acute and subacute . For complete data analysis, all the classes should have been shown in Table 2 including the number of treatment failures. Fourth, why were chosen, out of all categories in the DSM-IV, only anxiety disorders to be reported, was because it was the only one to be statistically significant? Fifth, why most of the chosen patients have such a high body mass index (BMI) (mean = 29 and SD = 7.5)? The relation between treatment response and BMI was not made clear, as it was not shown if patients with a lower BMI responded equally to the ones with high BMI. It is important to make this clear, since there are pharmacokinetic differences in the bioavailability between patients with high rates of fat and ones with lower rates. In addition, there may be different drug effects, considering the different metabolic rates between these two groups.Lastly, six patients dropped out of the trial, but the reasons were not revealed, was it side effects, lack of efficacy? ORCID iD
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.